grant
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY20250-11 years old2019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV S protein2019-nCoV spike glycoprotein2019-nCoV spike protein2019-nCoV vaccine21+ years old5 year old5 years of age7S Gamma GlobulinACE2Acute Laryngotracheo-Bronchitis VirusAcute Laryngotracheobronchitis VirusAdultAdult HumanAnimalsAntibodiesAntibody ResponseAttenuatedAttenuated VaccinesAvian ParamyxovirusesAvulavirusBlood SerumBovine SpeciesCA virusCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCOVID burdenCOVID-19COVID-19 S proteinCOVID-19 antibodyCOVID-19 antigenCOVID-19 burdenCOVID-19 disease burdenCOVID-19 health burdenCOVID-19 immunityCOVID-19 infectionCOVID-19 related burdenCOVID-19 spikeCOVID-19 spike glycoproteinCOVID-19 spike proteinCOVID-19 transmissionCOVID-19 vaccineCOVID-19 virusCOVID-19 virus infectionCOVID-19 virus transmissionCOVID19 infectionCOVID19 virusCV-19CattleCell Culture TechniquesChildChild YouthChildhoodChildren (0-21)Clinical EvaluationClinical ResearchClinical StudyClinical TestingClinical TrialsCoV-2CoV2CollaborationsComplementComplement ProteinsComplementary DNACoronavirus Infectious Disease 2019CricetinaeCroup-Associated VirusData AnalysesData AnalysisDiseaseDisorderDoseEpithelial CellsEvaluationFamilyGeneHomologGenerationsGenesHPIV2HPIV3HamstersHamsters MammalsHemadsorption Virus 1HomologHomologous GeneHomologueHumanHuman Parainfluenza Virus 2Human Parainfluenza Virus 3IgAIgGImmune responseImmunityImmunizationImmunizeImmunoglobulin AImmunoglobulin GIn VitroInfantInfectionInjectableLive-attenuated VaccineM mulattaM. mulattaMacacaMacaca mulattaMacaca rhesusMacaqueManuscriptsMiceMice MammalsModelingModern ManMorbidityMorbidity - disease rateMucosaMucosal Immune ResponsesMucosal ImmunityMucosal TissueMucous MembraneMurineMurine pneumonia virusMusOrthopneumovirusPara-Influenza Virus Type 2Para-Influenza Virus Type 3Parainfluenza Virus Type 2ParamyxoviridaeParamyxovirusPhasePhase I StudyPneumonia Virus of MicePneumoviridaePneumovirinaePneumovirusPreparationPrimatesPrimates MammalsProteinsPulmonary Body SystemPulmonary Organ SystemRecoveryRespiratory EpitheliumRespiratory SystemRespiratory TractsRespiratory syncytial virusRespiratory tract structureRhesus MacaqueRhesus MonkeyRouteSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 SSARS-CoV-2 S proteinSARS-CoV-2 antibodySARS-CoV-2 antigenSARS-CoV-2 burdenSARS-CoV-2 disease burdenSARS-CoV-2 immunitySARS-CoV-2 infectionSARS-CoV-2 infection burdenSARS-CoV-2 spikeSARS-CoV-2 spike glycoproteinSARS-CoV-2 spike proteinSARS-CoV-2 transmissionSARS-CoV-2 vaccineSARS-CoV2SARS-CoV2 infectionSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 vaccineSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SafetySamplingSerumSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 vaccineSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 S proteinSevere acute respiratory syndrome coronavirus 2 immunitySevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 spike glycoproteinSevere acute respiratory syndrome coronavirus 2 spike proteinSevere acute respiratory syndrome coronavirus 2 vaccineSevere acute respiratory syndrome related corona virus 2Structure of respiratory epitheliumSystemT-CellsT-LymphocyteT8 CellsT8 LymphocytesTransmissionTropismUpper respiratory tractVaccine DesignVaccinesVariantVariationViral VectorVirionVirus ParticleVirus ReplicationWuhan coronavirusadulthoodage 5 yearsairway epitheliumangiotensin converting enzyme 2angiotensin converting enzyme IIantibody against COVID-19antibody against SARS-CoV-2antibody against coronavirus disease 2019antibody against severe acute respiratory syndrome coronavirus 2antibody to COVID-19antibody to SARS-CoV-2antibody to coronavirus disease 2019antibody to severe acute respiratory syndrome coronavirus 2attenuateattenuatesattenuationbovidbovinecDNAcell culturecell culturesclinical testcommunity spreadcommunity transmissioncommunity-level spreadcommunity-level transmissioncomplementationcoronavirus disease 2019coronavirus disease 2019 S proteincoronavirus disease 2019 antibodycoronavirus disease 2019 antigencoronavirus disease 2019 immunitycoronavirus disease 2019 infectioncoronavirus disease 2019 spike glycoproteincoronavirus disease 2019 spike proteincoronavirus disease 2019 transmissioncoronavirus disease 2019 vaccinecoronavirus disease 2019 viruscoronavirus disease 2019 virus transmissioncoronavirus disease-19coronavirus disease-19 vaccinecoronavirus disease-19 viruscoronavirus infectious disease-19cowdata interpretationdesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccinefive year oldfive years of agehCoV19host responseimmune system responseimmunity against COVID-19immunity against SARS-CoV-2immunity against Severe acute respiratory syndrome coronavirus 2immunity against coronavirus disease 2019immunity to COVID-19immunity to SARS-CoV-2immunity to Severe acute respiratory syndrome coronavirus 2immunity to coronavirus disease 2019immunogenicityimmunoresponseimprovedinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2insightinterestkidslead candidatelife-threatening COVIDlife-threatening COVID-19life-threatening SARS-CoV-2life-threatening coronavirus diseaselife-threatening coronavirus disease 2019life-threatening severe acute respiratory syndrome coronavirus 2live vaccinelive vaccinesmanufacturemucosal vaccinemurine antibodynCoV vaccinenCoV-19 vaccinenCoV19 vaccinenCoV2neutralizing antibodynext generationnon-human primatenonhuman primateparainfluenza virusparainfluenza virus type 3pathogenpediatricphase 1 studyplasmid vaccinepre-clinical developmentpre-clinical studypreclinical developmentpreclinical studypreparationsprogramsprotective efficacyreceptor bindingreceptor boundresearch clinical testingrespiratoryrespiratory tract epitheliumrespiratory virusreverse geneticsserious COVIDserious COVID-19serious SARS-CoV-2serious coronavirus diseaseserious coronavirus disease 2019serious severe acute respiratory syndrome coronavirus 2severe COVIDsevere COVID-19severe COVID19severe SARS-CoV-2severe acute respiratory syndrome coronavirus 2 antibodysevere acute respiratory syndrome coronavirus 2 antigensevere acute respiratory syndrome coronavirus 2 transmissionsevere coronavirus diseasesevere coronavirus disease 19severe coronavirus disease 2019severe severe acute respiratory syndrome coronavirus 2spike proteins on SARS-CoV-2symptomatic COVID-19symptomatic COVID19symptomatic SARS-CoV-2 infectionsymptomatic coronavirus disease 2019thymus derived lymphocytetranslational goaltranslational missiontransmission processtransmitted COVID-19transmitted SARS-CoV-2transmitted coronavirus disease 2019transmitted severe acute respiratory syndrome coronavirus 2upper airway tractvaccination studyvaccination trialvaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine candidatevaccine candidates against SARS-CoV-2vaccine developmentvaccine for novel coronavirusvaccine responsevaccine responsivenessvaccine studyvaccine trialvaccine-induced responsevaccines preventing COVIDvaccines to prevent COVIDvariants of concernvectorvector vaccinevector-based vaccineviral multiplicationviral replicationvirus multiplicationyoungster
Description preview
We are developing parainfluenza virus- and pneumovirus-vectored vaccines for intranasal immunization against SARS-CoV-2. These viral vectors are designed to be highly attenuated in humans. They replicate to low levels in the superficial layers of the respiratory epithelium, and are optimized to induce strong local mucosal and systemic immune…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click